SCHEMBL6605571

SCHEMBL6605571

c1cc2cc(N3CCNCC3)ccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 4/20 0.56
HTR3B O95264 4/20 0.56
HTR3A P46098 4/20 0.56
HTR3D Q70Z44 4/20 0.56
HTR3C Q8WXA8 4/20 0.56
SIGMAR1 Q99720 4/20 0.56
HTR5A P47898 1/20 0.56
ADRB1 P08588 9/20 0.53
HTR1A P08908 4/20 0.48
HTR1D P28221 1/20 0.48
HTR1B P28222 1/20 0.48
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
HTR2C P28335 3/20 0.44
HTR7 P34969 2/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15515655 0.84 TERT (0.46) HTR3AHTR1ACYP1A2CYP2D6SLC6A4
SCHEMBL20954487 0.81 HTR3A (0.57) HTR3AHTR1ACYP2D6SLC6A4HTT
SCHEMBL22728519 0.80 SLC6A2 (0.42) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL10369679 0.80 SLC6A2 (0.57) HTR1ATP53CYP1A2CYP2D6SLC6A4
SCHEMBL22728587 0.76 BPTF (0.47) HTR1ACYP2D6SLC6A4
SCHEMBL17543352 0.75 SLC6A2 (0.42) HTR3AHTR1ATP53CYP2D6HTR2A
SCHEMBL23010425 0.74 ADRB1 (0.54) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18641248 0.74 KDM4E (0.48) HTR3AHTR1ACHEK1
SCHEMBL15244929 0.74 ADRB1 (0.53) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL11517673 0.73 CYP2A6 (0.50) SIGMAR1CHRM2CHRM1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113272292-B (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases 雅盖隆大学 2024-04-12 CN disclosed
EP-3908580-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES UNIWERSYTET JAGIELLONSKI (PL) 2021-11-17 EP disclosed
CN-113272292-A (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases 雅盖隆大学 2021-08-17 CN disclosed
WO-2020145831-A1 (2,5-DIOXOPYRROLIDIN-L-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES Uniwersytet Jagielloński (PL) 2020-07-16 WO disclosed
EP-1337528-B1 BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF VITA LAB (ES) 2004-08-04 EP disclosed
CN-1478088-A Benzothiophene derivatives, process for their preparation and their use ά��ʵ�������޹�˾ 2004-02-25 CN disclosed
US-20040034219-A1 Benzothiophene derivative compounds process of preparation and use thereof LABORATORIOS VITA, S.A. (ES) 2004-02-19 US disclosed
EP-1337528-A2 BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF LABORATORIOS VITA, S.A. (ES) 2003-08-27 EP disclosed
WO-2002044170-A2 BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF LABORATORIOS VITA, S.A. (ES) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034219-A1 Benzothiophene derivative compounds process of preparation and use thereof TPH1, HTR1A, HTR5A HTR3E 19/4885HTR3B 8/4885HTR3A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.